Gains on retirements of noncurrent assets included an €81 million gain from the sale of trademark rights for the Vagitrol™, Benadon™, Claradol™, Transipeg™ and Colopeg™ brands and some smaller brands (Consumer Health segment). In addition, a €49 million gain was realized on the sale of capitalized transfer rights by Bayer 04 Leverkusen Fußball GmbH (All Other Segments), Germany. In the Crop Science segment, a license agreement for herbicide active ingredients with FMC Corporation, United States resulted in income of €18 million..

Miscellaneous operating income includes a receivable relating to the nonfulifillment of a purchase obligation by one of our distribution partners in the amount of €34 million (Pharmaceuticals segment). The Crop Science segment received €25 million from insurers. A further €13 million was generated by the sale of research data following patent expirations (Crop Science segment). The transfer of a database to the joint venture Cooksonia Opco LLC, United States, with Ginkgo Bioworks, Inc., United States, brought additional income of €9 million for the Crop Science segment. In addition, a claim for damages of €8 million resulting from an infringement of a patent for Yasmin™ was recorded in the Pharmaceuticals segment.

Income from reversals of unutilized provisions included €9 million from the reversal of provisions for the Yasmin™ / YAZ™ litigation (2016: €104 million).

Furthermore, in 2016 miscellaneous operating income included a gain of €32 million at Bayer 04 Leverkusen Fußball GmbH from the sale of non-capitalized transfer rights (All Other Segments). In the Crop Science segment, milestone payments led to income of €21 million. In the Pharmaceuticals segment, a €14 million compensation payment was received in connection with the closure of the production site in Putuo, China. A €10 million gain (All Other Segments) was incurred on the sale of the BAYQUIK™ technology to Chemetics, Inc., Canada (Corporate Functions segment).